Skip to main content
. 2022 Aug 26;15(9):1055. doi: 10.3390/ph15091055

Figure 7.

Figure 7

AC16 cell line viability under normoxic and simulated ischemic conditions with or without varying concentrations of rosiglitazone. Results are presented as mean with standard error. The N + vehicle group was set to 100% RFU, and all data were normalized to the averaged N + vehicle group. Rosiglitazone treatment increased the viability of AC16 cells at 0.1 µM and 0.3 µM during simulated ischemia. (Kruskal–Wallis, Dunn’s post hoc, * p < 0.05 vs. SI + vehicle, # p < 0.05 vs. N + vehicle, n = 4, 32–39 technical replicates). SI: simulated ischemia; N: normoxia; veh: vehicle; rosi: rosiglitazone; RFU: relative fluorescence units.